Patients with chronic immune thrombocytopenia (ITP), not responding to corticosteroids (7 studies).
Eltrombopag, romiplostim, fostamatinib therapy or placebo.
Compared with placebo, avatrombopag was associated with statistically significant improvements in durable platelet response, reduction in use of concomitant ITP medication, and incidence of any bleeding events. Statistically significant differences vs. placebo were also observed for durable platelet response and need for rescue therapy (eltrombopag, romiplostim, and fostamatinib); reduction in use of concomitant ITP medication (eltrombopag and romiplostim); incidence of any bleeding events (fostamatinib); and incidence of WHO grade 2-4 bleeding events (romiplostim and fostamatinib). No statistically significant differences were observed for any adverse events. Avatrombopag was associated with a statistically significant lower incidence of any bleeding events vs. eltrombopag (IRR 0.38) and romiplostim (IRR 0.38); no other between-treatment differences were observed.